Mix Hotel on Lamarck Street
Sector: Hotel • Location: Paris, Île-de-France, France
Source: Voyages d'affaires
A large development project on Lamarck Street, 18th arrondissement, Paris, over 15,000 m² including housing with social housing and a hotel combining sport, accommodation, catering, and meeting rooms. The hotel concept is Mix Hotel, a Belgian brand.
- Status
- Prospective
- Sector
- Hotel, Road
- Location
- Paris, Île-de-France, France
- Updated
- 22 Jul 2026
- Source
- Voyages d'affaires
ConstructChat
Ask ConstructChat about Mix Hotel on Lamarck Street
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | planned |
Taiyo status | Prospective |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | A large development project on Lamarck Street, 18th arrondissement, Paris, over 15,000 m² including housing with social housing and a hotel combining sport, accommodation, catering, and meeting rooms. The hotel concept is Mix Hotel, a Belgian brand. |
Original sector | Built Sector |
Location
Country | France |
State | Île-de-France |
City | Paris |
Source
Source | Voyages d'affaires |
URL |
More Details
Record type | Project |
Sector | Hotel, Road |
Article published date | 2026-04-19 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hotel projects in France
- Mama Shelter Hotels
- Genzyme Biomanufacturing Plant
- AstraZeneca Symbicort Production Facility, Dunkirk
- Sanofi’s Evolutive Vaccine Facility (EVF), Neuville-sur-Saône
- Ferring Pharmaceuticals Biotechnology Centre, Saint-Prex, Switzerland
- Yposkesi’s Cell and Gene Therapy Facility, Corbeil-Essonnes, France
- Univercells’ Cell and Gene Therapy Manufacturing Facility, Jumet, Belgium
- Phase IIb/III Clinical Trial in ndGBM patients
